---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-26-000053"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:33:19.157929+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Halozyme names Darren Snellgrove as CFO, effective June 8, 2026

## Summary
- Darren Snellgrove appointed CFO effective June 8, 2026; previously VP IR at Johnson & Johnson and CFO of its Pharmaceuticals sector.
- Compensation: $670,000 annual salary, 50% bonus target, $350,000 sign-on cash bonus, and $7.2M new-hire equity awards ($3.2M RSUs + $4M options).
- 2027 long-term incentive minimum $4M; make-whole RSUs vest over 3 years, stock options vest 25% after 1 year then monthly.
- David Ramsay, interim CFO, will assume advisory role effective June 8, 2026 to assist transition.
- Snellgrove holds MBA from Villanova, BA from University of Southampton; no family relationships or material interests in transactions.

## SEC filing metadata
- accession: 0001159036-26-000053
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000053/0001159036-26-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000053/halo-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-26-000053
- JSON: https://secwatch.observer/filing/0001159036-26-000053.json
- Plain text: https://secwatch.observer/filing/0001159036-26-000053.txt

## Key facts
- Executive change
  David Ramsay changed role as Interim CFO at HALOZYME THERAPEUTICS, INC..
  - Action: will assume an advisory role
  - Role: Interim CFO
  source text: Effective as of June 8, 2026, David Ramsay, the Company’s current Interim CFO, will assume an advisory role with the Company to assist during a brief transition period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000053/0001159036-26-000053-index.htm
- Executive change
  Darren Snellgrove was appointed as Chief Financial Officer at HALOZYME THERAPEUTICS, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On April 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), effective June 8, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000053/0001159036-26-000053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.